Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Holdings Boosted by Great Point Partners LLC

Great Point Partners LLC lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 21.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 757,929 shares of the company’s stock after purchasing an additional 132,929 shares during the period. Dianthus Therapeutics comprises 3.8% of Great Point Partners LLC’s investment portfolio, making the stock its 10th biggest position. Great Point Partners LLC owned about 2.58% of Dianthus Therapeutics worth $19,615,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of DNTH. Bain Capital Life Sciences Investors LLC acquired a new stake in Dianthus Therapeutics in the 1st quarter worth about $89,761,000. RA Capital Management L.P. acquired a new stake in shares of Dianthus Therapeutics in the first quarter worth approximately $69,990,000. Octagon Capital Advisors LP boosted its stake in shares of Dianthus Therapeutics by 15.4% in the fourth quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock worth $5,762,000 after acquiring an additional 74,000 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Dianthus Therapeutics by 250.0% during the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after purchasing an additional 384,182 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new position in Dianthus Therapeutics in the 1st quarter valued at $11,251,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

DNTH stock opened at $26.17 on Tuesday. The firm has a market cap of $768.06 million, a PE ratio of -4.49 and a beta of 1.85. Dianthus Therapeutics, Inc. has a one year low of $6.58 and a one year high of $33.77. The firm’s 50 day moving average price is $27.92 and its 200-day moving average price is $26.17.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The business had revenue of $1.86 million during the quarter, compared to analysts’ expectations of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. Equities research analysts predict that Dianthus Therapeutics, Inc. will post -2.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald started coverage on shares of Dianthus Therapeutics in a report on Thursday, June 27th. They set an “overweight” rating for the company. Lifesci Capital raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Wedbush decreased their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, August 12th. Finally, Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Dianthus Therapeutics currently has an average rating of “Buy” and an average target price of $44.71.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.